Searchable abstracts of presentations at key conferences in endocrinology

ea0094oc6.6 | Metabolism, Obesity and Diabetes | SFEBES2023

Low carbohydrate diets in Type 1 diabetes – defining the degree of glycaemic control and nutritional ketosis

Ozoran Hakan , Karpe Fredrik , Dyson Pam , Tan Garry , Matheou Michael

Background: Carbohydrate-restricted diets in type 1 diabetes mellitus (T1DM) are highly controversial. A commonly held concern is that a low carbohydrate diet may more readily result in conversion to diabetic ketoacidosis – one of the most severe complications of poorly managed T1DM. Of note, there is no clear evidence for this phenomenon. We evaluated metabolic profiles in patients with T1DM who had self-selected carbohydrate-restricted diets.<p clas...

ea0094p346 | Metabolism, Obesity and Diabetes | SFEBES2023

Modelling muscle wasting in chronic kidney disease under conditions of acidosis and steroid exposure

Hussain Alisha , Dinouri Rania , Crastin Ana , Sagmeister Michael , Hardy Rowan

Introduction: Chronic kidney disease (CKD) is characterised by an ongoing reduction in kidney function and is associated with comorbidities such as muscle wasting that greatly increase mortality. Both acidosis and elevated glucocorticoids levels are hallmarks of CKD and implicated as having a synergistic role in driving muscle wasting. We investigated the synergistic effects of acidosis and the glucocorticoid cortisol on muscle metabolism and fibre size using ...

ea0095p97 | Diabetes 3 | BSPED2023

Disparities in using an insulin pump to manage Type1 DM Evelina Children’s Hospital experience

Haj-Ahmed Eiman , Wiles Lillian , Cornish Michael , Regan Fiona

Introduction: In recent years there has been a highlight on the inequity of diabetes care and results across the UK. Research needs to be taken into barriers of access to technology for type 1 diabetes in CYP in the UK, specifically looking at provider bias, systemic issues within the health system, and individual and family factors.Aim of the study: We explored the potential factors that might affect access to technolog...

ea0099rc5.6 | Rapid Communications 5: Pituitary and Neuroendocrinology | Part I | ECE2024

Etiology, treatment, and outcomes of sellar metastases: A single-center institutional experience

Breu Julia , Zhao Yining , Buchfelder Michael , Kremenevski Natalia

Background: Metastases to the sellar region are extremely rare tumours in surgical series. The reported incidence has recently increased with advances in neuroimaging. Survival of patients with metastatic cancer has improved due to progress in oncologic therapies and diagnostics. Patients with sellar metastases (SM) follow a variable disease course that is not well defined.Objective: The objective was to evaluate the clinical characteristics, surgical ap...

ea0099p128 | Pituitary and Neuroendocrinology | ECE2024

Posterior pituitary tumours: a single institutional experience of 19 patients

Kremenevski Natalia , Zhao Yining , Roland Coras , Buchfelder Michael

Background: Posterior pituitary tumors (PPTs) present as clinically nonfunctioning space-occupying lesions of the sellar region. The diagnosis of PPTs is not possible on the basis of their clinical, radiological and biochemical features. Immunohistochemistry identifies them for their expression of TTF. They are virtually always mistakenly defined as one of the more common pituitary tumours. Due to their rarity, the long-term endocrine aspects and outcomes of PPTs are not well ...

ea0099ep331 | Calcium and Bone | ECE2024

Denosumab therapy in diffuse sclerosing osteomyelitis – a case report

Vahidi Rad Mona , Ahmed Samir , Whitaker Michael , Kumar Aditi

Introduction: Diffuse sclerosing osteomyelitis (DSO) of the jaw is a chronic and rare condition that can present with recurrent and severe jaw pain and mandibular swelling. The treatment of this condition can often be quite challenging. We present a patient with mandibular DSO who had significant improvement in jaw pain with denosumab injections. Clinical Case: A 23-year-old female presented with left mandible pain for 4 years. Her symptoms started after...

ea0090oc8.2 | Oral Communications 8: Calcium and Bone | ECE2023

Eneboparatide, a Novel PTH-1 Receptor Agonist, Has No Impact on Bone Parameters Following Chronic Treatment of Non-Human Primates

Ravel Guillaume , Delale Thomas , Milano Stephane , Chirat Sophie , Verset Michael , Latronico Emilie , Allas Soraya , Culler Michael D.

Eneboparatide (AZP-3601) is a novel, synthetic, 36-amino-acid peptide agonist of the parathyroid hormone type 1 receptor (PTHR1), with potent selectivity for the R0 conformation. This results in prolonged calcemic responses, while having a short circulating half-life. Eneboparatide is being developed for the treatment of chronic hypoparathyroidism (cHP). Studies in hypoparathyroid animal models and, most recently, in hypoparathyroid patients, have demonstrated that eneboparati...

ea0090rc10.5 | Rapid Communications 10: Diabetes, Obesity, Metabolism and Nutrition 2 | ECE2023

Metformin counteracts adverse metabolic effects of glucocorticoids in healthy subjects

Thierry Susanne , Peterson Caspar Joyce , Delko Tarik , Iten Vasco , Epstein Michael , Kuhne Michael , Meyer-Zurn Christine , Seelig Eleonora

Background: Glucocorticoids are powerful anti-infla mmatory drugs. However, metabolic side effects are common and limit their long-term use. Furthermore, the underlying mechanisms of adverSemetabolic effects are not well known, and this lack of knowledge results in poor treatment. We have previously shown that the antidiabetic drug metformin prevents glucocorticoid-induced metabolic effects in older, sick patients. Here, we investigate metformin in a young and healthy populati...

ea0042p28 | (1) | Androgens2016

Evidence for neuroendocrine progenitor cells in a transgene mouse model of prostate cancer

Udovica Simon , Otahal Alexander , Tomasich Erwin , Heller Gerwin , Schwarz Michael , Spittler Andreas , Horvat Reinhard , Horak Peter , Marhold Maximilian , Krainer Michael

In developed countries, prostate cancer (PCa) is the most prevalent cancer and the second most common cause of cancer related death in males. Tumors from patients exhibiting disease progression after systemic androgen deprivation treatment (ADT), referred to as castration resistant prostate cancer (CRPC), often show differentiation towards an aggressive phenotype – neuroendocrine prostate cancer or NE-PC. In our study, we used the Simian-Virus 40 (SV-40) T-antigen driven ...

ea0038p360 | Reproduction | SFEBES2015

Whole exome sequencing in congenital hypogonadotropic hypogonadism

Izatt Louise , Carroll Paul , Lillis Suzanne , Brodd Lina , Stone Kristina , Ryan Kevin , Ahn JooWook , Simpson Michael , Yau Michael

Congenital hypogonadotropic hypogonadism (CHH (MIM161110)) due to GnRH deficiency is a rare genetic disorder (affects ~1/30 000) characterised by abnormal pubertal development and infertility. Over 60% cases have anosmia (Kallmann syndrome) and some exhibit additional phenotypes. CHH is a genetically heterogeneous developmental disease. Most cases present sporadically, although familial forms (AD, AR, and X-linked) with incomplete penetrance and variable expressivity occur. Re...